miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth

Yuyan Han1, Fanyin Meng2, Julie Venter3

  • 1Research, Central Texas Veterans Health Care System, United States; Department of Medicine, Texas A&M Health Science Center, United States.

Journal of Hepatology
|March 1, 2016
PubMed
Abstract

Insights

Disruption of the circadian rhythm gene Per1 is linked to bile duct cancer growth. Restoring Per1 levels and rhythm in cholangiocarcinoma cells reduced tumor growth and improved cell death, offering potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Chronobiology

Background:

  • Disruption of circadian rhythm is implicated in cancer development and progression.
  • MicroRNAs (miRNAs) are key regulators of gene expression, influencing cellular processes.
  • The role of the core clock gene Per1 and associated miRNAs in cholangiocarcinoma (CCA) remains underexplored.

Purpose of the Study:

  • To investigate the expression and function of Per1 in human cholangiocarcinoma.
  • To elucidate the regulatory relationship between Per1 and microRNA-34a (miR-34a) in CCA.
  • To assess the therapeutic potential of targeting Per1 or miR-34a in cholangiocarcinoma.

Main Methods:

  • Quantitative real-time PCR (qPCR) to assess clock gene expression in CCA tissues and cell lines.
  • Cell proliferation, cell cycle, and apoptosis assays following Per1 overexpression or miR-34a inhibition.
  • In vivo tumor growth studies in immunocompromised mice and mRNA profiling to identify molecular pathways.

Main Results:

  • Per1 expression was significantly decreased, and its circadian rhythm was lost in CCA cells.
  • Per1 overexpression reduced cell proliferation, induced G2/M arrest, enhanced apoptosis, and inhibited tumor growth, angiogenesis, and metastasis in vivo.
  • Per1 was identified as a direct target of miR-34a; miR-34a inhibition decreased CCA cell proliferation, migration, and invasion.

Conclusions:

  • Loss of Per1 expression and circadian rhythm disruption contribute to the malignant phenotype of cholangiocarcinoma.
  • Modulating Per1 or miR-34a levels offers a promising therapeutic strategy for cholangiocarcinoma.
  • Per1 influences cancer-related pathways, including cell cycle, growth, and apoptosis, highlighting its critical role in CCA pathogenesis.

Related Concept Videos